Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychotic Episode Clear all
Completed Not applicable Interventional

Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis

NCT00307216
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia
Interventions
Graduated Recovery Intervention Program (GRIP), Treatment as usual (TAU)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927
View directory record Official record
Conditions
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Dothan, Alabama • Downey, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Not applicable Interventional

Digital Strategies to Advance Help-Seeking - Aim 3

NCT06774417
View directory record Official record
Conditions
Clinical High Risk, Early Psychosis, First Episode Psychosis
Interventions
Digital nudge
Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 29 Years
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 1Phase 2 Interventional

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT00694889
View directory record Official record
Conditions
Schizophrenia
Interventions
Neuroadaptive cognitive training, Computer games
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 35 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

First Episode Schizophrenia and Cannabis-Related Disorder Study

NCT00573287
View directory record Official record
Conditions
Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
Interventions
clozapine, risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
17 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Concord, New Hampshire • Lebanon, New Hampshire • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 19, 2026, 12:32 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

NCT05890768
View directory record Official record
Conditions
Psychosis
Interventions
Lumateperone, Risperidone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Not yet recruiting Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

NCT06923891
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline/Trospium
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 19, 2026, 12:32 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

NCT04005378
View directory record Official record
Conditions
First Episode Psychosis
Interventions
CSC Step-down intervention, Usual Care
Other
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Lauderdale Lakes, Florida • Grand Rapids, Michigan • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCT04203056
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder
Interventions
Aripiprazole Lauroxil, ARI-ORAL, AL-NCD
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Phase 4 Interventional Results available

Optimizing Response in Psychosis Study

NCT00314327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Brooklyn, New York • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 19, 2026, 12:32 PM EDT
Withdrawn Phase 3 Interventional

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

NCT02212613
View directory record Official record
Conditions
Major Depressive Disorder and Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 19, 2026, 12:32 PM EDT
Terminated Not applicable Interventional

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

NCT04368039
View directory record Official record
Conditions
Psychosis, Schizophrenia, First-episode Psychosis
Interventions
Normobaric Oxygen, Placebo
Device
Lead sponsor
Nicholas Breitborde
Other
Eligibility
15 Years to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 19, 2026, 12:32 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation

NCT05112432
View directory record Official record
Conditions
Psychosis
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Duluth, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Enrolling by invitation Not applicable Interventional

California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis

NCT04007510
View directory record Official record
Conditions
First Episode Psychosis (FEP)
Interventions
EPI-CAL data network, Community DUP Assessment Tool
Combination Product · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 40 Years
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis

NCT01196286
View directory record Official record
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of Motivational Interviewing for Loved Ones

NCT04010747
View directory record Official record
Conditions
Psychotic Disorders, Psychosis, Psychotic Episode
Interventions
Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 19, 2026, 12:32 PM EDT
Recruiting Not applicable Interventional

Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

NCT05890183
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST), Chorus Participatory Text Messaging Program, Healthy Living Group (HLG)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomarkers in First Episode Schizophrenia

NCT02033382
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 19, 2026, 12:32 PM EDT
Completed No phase listed Observational

Reducing the Duration of Untreated Psychosis

NCT03102151
View directory record Official record
Conditions
First Episode Psychosis
Interventions
Community Campaign La CLAVE
Other
Lead sponsor
University of Southern California
Other
Eligibility
15 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Granada Hills, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 19, 2026, 12:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 12:32 PM EDT
Completed No phase listed Observational

Reducing the Duration of Untreated Psychosis in the United States

NCT03369730
View directory record Official record
Conditions
First Episode Psychosis (FEP), At Risk Mental State (ARMS)
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 30 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 19, 2026, 12:32 PM EDT